Emergent Biosolutions (NYSE:EBS) Share Price Crosses Above 200 Day Moving Average – Should You Sell?

Emergent Biosolutions Inc. (NYSE:EBS) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.46 and traded as high as $12.60. Emergent Biosolutions shares last traded at $12.1760, with a volume of 669,411 shares changing hands.

Wall Street Analysts Forecast Growth

EBS has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research report on Friday, October 24th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $15.00.

Emergent Biosolutions Stock Performance

The stock has a market cap of $639.48 million, a price-to-earnings ratio of 9.37 and a beta of 2.30. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14. The company has a 50 day simple moving average of $11.61 and a 200 day simple moving average of $9.46.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $1.18. The company had revenue of $231.10 million for the quarter, compared to analyst estimates of $203.67 million. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. As a group, equities research analysts forecast that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Buying and Selling at Emergent Biosolutions

In related news, Director Ronald Richard sold 21,984 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the sale, the director owned 98,417 shares in the company, valued at $1,178,051.49. The trade was a 18.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc acquired a new stake in Emergent Biosolutions during the 2nd quarter worth approximately $31,000. Ameritas Investment Partners Inc. bought a new stake in shares of Emergent Biosolutions in the second quarter worth $35,000. Raymond James Financial Inc. bought a new stake in shares of Emergent Biosolutions in the second quarter worth $53,000. Janney Montgomery Scott LLC acquired a new stake in Emergent Biosolutions in the second quarter valued at $68,000. Finally, BNP Paribas Financial Markets raised its position in Emergent Biosolutions by 133.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,942 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 6,246 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.